CD79A and COVID-19: To determine if the vaccine-induced immune responses in our low-transmission study cohort align with previous observations, where robust antibody responses have been described after two COVID-19 vaccine doses, we measured IgG, IgM, and IgA antibody levels to several Spike protein-derived SARS-CoV-2 antigens including the receptor binding domain (RBD; Fig. 1A), S1, S2, Spike trimer, and the nucleoprotein (Fig. S3) in previously SARS-CoV-2 uninfected (naïve) individuals and in individuals who had recovered from SARS-CoV-2 infection (convalescent).